Lts Lohmann Therapie-systeme Ag

Lts Lohmann Therapie-systeme Gmbh

Lts Lohmann Therapie-systeme Gmbh + Co. Kg

Lts Lohmann Therapie Systeme Gmbh & Co.

Other

Lts Lohman Therapie-systeme Gmbh & Co. Kg

Lothar Deurer

Thomas Hille

Peter Steinborn

Dieter Anhauser

Ludwig Grader

Hans-Rainer Hoffmann

Fritz Stanislaus

Thomas Profitlich

Kersten Walter

Karlheinz Otto

The invention relates to transdermal therapeutic systems (TTS) comprising a backing, a reservoir layer containing at least one pharmaceutical active ingredient, and an adhesive. Said transdermal therapeutic systems are characterised in that they are able to continuously adhere to the surface of the skin over a long period of time. During said long period of time, a) there is at least one time interval during which the TTS adhering to the surface of the skin is intensively exposed to water, and b) the active ingredient is transdermally released. The invention also relates to a method for the continuous transdermal release of at least one pharmaceutical active ingredient over a long period of time.

Transdermal therapeutic system having improved long-term wearing comfort

Buprenorphine transdermal therapeutic system and method of administering

The invention relates to transdermal therapeutic systems (TTS) comprising a backing, a reservoir layer containing at least one pharmaceutical active ingredient, and an adhesive. Said transdermal therapeutic systems are characterized in that they are able to continuously adhere to the surface of the skin over a long period of time. During said long period of time, a) there is at least one time interval during which the TTS adhering to the surface of the skin is intensively exposed to water, and b) the active ingredient is transdermally released. The invention also relates to a method for the continuous transdermal release of at least one pharmaceutical active ingredient over a long period of time.

Transdermal rivastigmine therapeutic system

Transdermal therapeutic buprenorphine system

Transdermal therapeutic system provided with improved long-term carrying comfort

A transdermal therapeutic system (TTS), in particular a patch, is described, comprising:

Transdermal therapeutic system comprising a reservoir type pressure sensitive adhesive layer and a back layer with uni-directional resilience

Transdermal therapeutic system comprising a reservoir-type pressure-sensitive adhesive layer and a back layer with uni-directional resilience

The invention relates to a transdermal therapeutic system (TTS) containing desoxypeganine (1,2,3,9-Tetrahydropyrrolo&lsqb;2,1-b&rsqb;quinazoline) as the active component, wherein the TSS includes a back layer impermeable to desoxypeganine and an adhesive reservoir layer that contains 10-80 weight percent polymeric material, 0.1-30 weight percent desoxypeganine and/or the pharmaceutically acceptable salts thereof and optionally a softening agent in proportions of 0.1-30 weight percent.

Desoxypeganine

A process for continuously manufacturing transdermal therapeutic patches having a backing layer, a pressure-sensitive adhesive drug reservoir layer, and a removable protective layer, whereby loss of active substances during fabrication of the patches is minimized, said process being characterized in that, in a tape-like laminate having a pressure-sensitive adhesive backing layer (,) and a removable protective layer (,), single quadrangular pressure-sensitive adhesive drug reservoir sections (,) are inserted one after the other in the longitudinal direction between the layers (,); the clearance between said drug reservoir sections remains constant in the longitudinal direction; their width is calculated such that the backing layer (,) and the removable protective layer (,) project beyond both sides of said sections; the pressure-sensitive adhesive backing layer (,) is first cut by punching in such a way that the punching line (,) surrounds the individual drug reservoir sections (,) at an evident distance from their outer dimensions; the the resulting lattice-type refuse of the drug-free pressure-sensitive adhesive backing layer (,) is removed; and subsequently the protective layer (,) is cut in the resultant spaces between the drug reservoir sections (,).

Transdermal therapeutic plaster

Method for the transfer of sections that are self-adhesive on one side

Systems for the controlled release of pilocarpine

Transdermal therapeutic system comprising galanthamine as active

Transdermal therapeutic system for the administration of physostigmine

Production of transdermal therapeutic systems

The controlled release of buprenorphine or the pharmaceutically acceptable salts thereof to the skin over a period of time of at least 24 hours is ensured by a transdermal therapeutic system consisting of a backing layer which is impermeable to the active substance, a pressure-sensitive adhesive reservoir layer, and optionally a removable protective layer. Said reservoir layer of said system comprises 20 to 90%-wt polymeric material, 0.1 to 30%-wt softener, 0.1 to 20%-wt buprenorphine base or one of the pharmaceutically acceptable salts thereof, and 0.1 to 30%-wt solvent for the active substance base.

Transdermal therapeutic system comprising as active component

Growing community of inventors

Koblenz, Germany

Lothar Deurer